个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共16条记录   New generation azole antifungals in clinical investigation (vol 18, pg 1279, 2009) [作者：Girmenia, C,期刊：Expert opinion on investigational drugs, 页码：1967-1967 , 文章类型： Correction，,卷期：2009年18-12] Seliciclib in malignancies [作者：Aldoss, IT; Tashi, T; Ganti, AK,期刊：Expert opinion on investigational drugs, 页码：1957-1965 , 文章类型： Editorial Material，,卷期：2009年18-12] Cyclins and cyclin-dependent kinases (CDK) form a key part of the regulatory proteins that govern the cell cycle. Aberrancy in their function can lead to uncontrolled growth and proliferation of the cells which forms the... Investigational drugs in sickle cell anemia [作者：Kotiah, SD; Ballas, SK,期刊：Expert opinion on investigational drugs, 页码：1817-1828 , 文章类型： Review，,卷期：2009年18-12] Sickle cell anemia is one of the most common autosomal recessive diseases in the world. Patients with sickle cell anemia have variable penetrance and it is hard to predict the risk and timing of complications. It is char... Discontinued drugs 2008: pulmonary and allergy [作者：Antoniu, SA,期刊：Expert opinion on investigational drugs, 页码：1799-1805 , 文章类型： Article，,卷期：2009年18-12] This is the annual perspectives paper on discontinued drugs in the field of pulmonary disease and allergy. It is part of a series of papers discussing drugs dropped from clinical development in the previous year and pres... Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals [作者：March, B; Cardi, T,期刊：Expert opinion on investigational drugs, 页码：1807-1815 , 文章类型： Article，,卷期：2009年18-12] Objective: To characterize the effects of a sustained-release formulation of fampridine (fampridine-SR) on QT interval in healthy subjects. Methods: in a double-blind, double-dummy trial, healthy subjects were randomized... Tachykinin receptor antagonists in clinical trials [作者：Quartara, L; Altamura, M; Evangelista, S; Maggi, CA,期刊：Expert opinion on investigational drugs, 页码：1843-1864 , 文章类型： Review，,卷期：2009年18-12] Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and... Investigational therapies for celiac disease [作者：Rodrigo, L,期刊：Expert opinion on investigational drugs, 页码：1865-1873 , 文章类型： Review，,卷期：2009年18-12] Celiac disease is an autoimmune condition affecting genetically susceptible individuals. It is produced by the ingestion of gluten contained in wheat, rye, barley, and related products. The only treatment currently avail... New and investigational antiepileptic drugs [作者：Striano, P; Striano, S,期刊：Expert opinion on investigational drugs, 页码：1875-1884 , 文章类型： Review，,卷期：2009年18-12] In the last fifteen years, new antiepileptic medications have been offered for the treatment of patients with epilepsy. Nevertheless, despite optimal medical treatment, up to 30% of patients still experience recurrent se... Small-molecule inhibitors of the human epidermal receptor family [作者：Carter, CA; Kelly, RJ; Giaccone, G,期刊：Expert opinion on investigational drugs, 页码：1829-1842 , 文章类型： Review，,卷期：2009年18-12] Background: Small molecule inhibitors of human epidermal receptors (HER) have become an integral part of the armamentarium available to the medical oncologist in the treatment of solid tumor malignancies. At present, the... Arimoclomol: a potential therapy under development for ALS [作者：Lanka, V; Wieland, S; Barber, J; Cudkowicz, M,期刊：Expert opinion on investigational drugs, 页码：1907-1918 , 文章类型： Editorial Material，,卷期：2009年18-12] Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with ari... Polidocanol for endovenous microfoam sclerosant therapy [作者：Eckmann, DM,期刊：Expert opinion on investigational drugs, 页码：1919-1927 , 文章类型： Editorial Material，,卷期：2009年18-12] Background: Polidocanol is a liquid surfactant having endothelial cell lytic properties. in the form of a controlled, dispensed microfoam it is administered endovenously as a sclerosing agent in the treatment of varicose... The rationale for mTOR inhibition in epithelial ovarian cancer [作者：Trinh, XB; van Dam, PA; Dirix, LY; Vermeulen, PB; Tjalma, WAA,期刊：Expert opinion on investigational drugs, 页码：1885-1891 , 文章类型： Review，,卷期：2009年18-12] The AKT/mTOR signaling pathway is frequently overexpressed in human epithelial ovarian cancer and an attractive target for therapy. In vivo mouse models were confirmative for in vitro findings, where the administration o... The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer [作者：Yong, HY; Koh, MS; Moon, A,期刊：Expert opinion on investigational drugs, 页码：1893-1905 , 文章类型： Review，,卷期：2009年18-12] Background: The p38 mitogen-activated protein kinase (MAPK) is activated by various pro-inflammatory and stressful stimuli. Mounting evidence suggests that the p38 MAPK signaling cascade is involved in various biological... Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency [作者：Kaminetsky, J; Hemani, ML,期刊：Expert opinion on investigational drugs, 页码：1947-1955 , 文章类型： Editorial Material，,卷期：2009年18-12] Hypogonadism has a number of important clinical consequences related to androgen deficiency and impaired spermatogenesis. The cause of this condition is multifactorial and can result from hypothalamic, pituitary or gonad... Vernakalant hydrochloride for the treatment of atrial fibrillation [作者：Kozlowski, D; Budrejko, S; Lip, GYH; Mikhaildis, DP; Rysz, J; Raczak, G; Banach, M,期刊：Expert opinion on investigational drugs, 页码：1929-1937 , 文章类型： Editorial Material，,卷期：2009年18-12] Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Rhythm control strategy for AF is limited by drug toxicity and side effects, and recent trials have shown that this strategy is not... Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity [作者：Lorusso, D; Mainenti, S; Pietragalla, A; Ferrandina, G; Foco, G; Masciullo, V; Scambia, G,期刊：Expert opinion on investigational drugs, 页码：1939-1946 , 文章类型： Editorial Material，,卷期：2009年18-12] Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity dramatically reduced compared with other minor groove DNA-binding agents. In the presence of high in...